NDC 63020-040
EXKIVITY
Mobocertinib
EXKIVITY is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Takeda Pharmaceuticals America, Inc.. The primary component is Mobocertinib.
| Product ID | 63020-040_46bccc44-788b-444f-a47d-8b6e8f81d30b |
| NDC | 63020-040 |
| Product Type | Human Prescription Drug |
| Proprietary Name | EXKIVITY |
| Generic Name | Mobocertinib |
| Dosage Form | Capsule |
| Route of Administration | ORAL |
| Marketing Start Date | 2021-09-15 |
| Marketing Category | NDA / |
| Application Number | NDA215310 |
| Labeler Name | Takeda Pharmaceuticals America, Inc. |
| Substance Name | MOBOCERTINIB |
| Active Ingredient Strength | 40 mg/1 |
| Pharm Classes | Cytochrome P450 3A Inducers [MoA], HER1 Antagonists [MoA], Kinase Inhibitor [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
Packaging
NDC 63020-040-12
120 CAPSULE in 1 BOTTLE (63020-040-12)
| Marketing Start Date | 2021-09-15 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Drug Details
Trademark Results [EXKIVITY]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 EXKIVITY 90046914 not registered Live/Pending |
Takeda Pharmaceuticals International AG 2020-07-10 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.